Cronos Group Inc.
Cronos Group Inc. (CRON): 8 pipeline candidates · 8 upcoming catalysts · ~122 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
122.0 months
D/E 0.04 · 1% dilution
Lead: Approved
8 candidates
8 upcoming, next in ~43d
N/A
A transparent, data-derived signal for Cronos Group Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$984.6M
Cash
$821.9M
Quarterly Burn
$21.0M
Runway
122.0 mo
Revenue
$59.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| LIT | — |
| Lord Jones | — |
| Lord Jones® | — |
| nystatin | Approved |
| PEACE NATURALS | — |
| PEACE NATURALS® | — |
| Spinach | — |
| Spinach® | — |
Upcoming Catalysts (8)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$85.8M
| Holder | Shares | Value |
|---|---|---|
| d. e. shaw & co., inc. | 7,618,227 | $19.1M |
| dimensional fund advisors lp | 2,679,051 | $6.7M |
| susquehanna international group, llp | 2,169,367 | $5.4M |
| renaissance technologies llc | 2,009,549 | $5.0M |
| prelude capital management, llc | 1,500,000 | $3.8M |
| cibc world market inc. | 1,346,820 | $3.4M |
| jane street group, llc | 1,043,675 | $2.6M |
| mmcap international inc. spc | 999,490 | $2.5M |
| quinn opportunity partners llc | 969,033 | $2.4M |
| cdc financial, inc. | 926,832 | $2.3M |
Showing top 10 of 189 institutional holders of Cronos Group Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cronos Group Inc.'s pipeline?
Cronos Group Inc. (CRON) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cronos Group Inc.'s next catalyst?
Cronos Group Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ACTOPLUS MET XR" — expected July 31, 2026.
What is Cronos Group Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cronos Group Inc. has approximately 122.0 months of cash runway.
What is Cronos Group Inc.'s market capitalization?
Cronos Group Inc.'s market capitalization is approximately $984.6M.
Who is the CEO of Cronos Group Inc.?
Mr. Michael Ryan Gorenstein J.D. is the chief executive officer of Cronos Group Inc. (CRON).
Get the full picture on Cronos Group Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.